Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.30 -1.94% 15.20 578,617 08:00:11
Bid Price Offer Price High Price Low Price Open Price
15.10 15.30 15.20 15.20 15.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.35 -6.33 -1.50 66
Last Trade Time Trade Type Trade Size Trade Price Currency
16:15:04 O 60,000 15.20 GBX

Kromek (KMK) Latest News

More Kromek News
Kromek Investors    Kromek Takeover Rumours

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
22/10/202117:33Kromek Group PLC5,344
21/8/201710:01Kromek Group (KMK) - Overvalued AIM mugging181

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

Kromek Daily Update: Kromek Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 15.50p.
Kromek Group Plc has a 4 week average price of 15.03p and a 12 week average price of 15.03p.
The 1 year high share price is 25.10p while the 1 year low share price is currently 10.10p.
There are currently 431,851,820 shares in issue and the average daily traded volume is 730,708 shares. The market capitalisation of Kromek Group Plc is £65,641,476.64.
b00mb0y: “Status Quo” down down deeper and down. KMK share price “ down down deeper and down. Status quo- the current state of affairs
b00mb0y: AQC888. As you are aware, i have been saying this for quite sometime now (maybe with some irritating quotes) only to be shot down by rampers who simply won't have a wrong word said about KMK and the share price There are many more that feel the way I do about this stock including, i now think, you. We have all heard and seen the "good news and great news repots/videos" but the share price drifts lower and lower after such reports. On this basis alone this tells me that there is something seriously wrong here and underhanded goings on is happening. I can't guarantee but I believe that a particular poster on here is without doubt ramping this stock as his posts are particularly timed at coming out and can also be repetitive. Not that this would have any affect on the share price but trying to keep investors holding and to influence newbies. Anyway, as the share price drops I wish you well.
aqc888: Boomboy, the market seems not to acknowledging that this detector is worth anything. Forecasts for Kromek are based on the rest of the business without the detector. My point is that at some point this detector, which appears to work - both the covid and wide spectrum version and will need to be included in the valuation. This will probably only happen when there is some news regarding it which causes excitement- probably news of buys from various recognised institutions. Or news of exactly how effect it is, not just vague statements about it doing very well similar to pcr etc. I’m not sure why the accreditation report wasn’t released. I’d like to see the report for myself, not a summary by Kromek of how excellent the report says their machine is. There is still enough doubt regarding the detector for it not to effect the share price. None of us know for certain still if it really will work. With this doubt lingering over Kromek the price will remain around 17p. My point is that if and when proof, in the form of sales to institutions starts, the Kromek share price will suddenly re-rate. Or maybe we’re all being taken in as suckers and there is no detector that works, which in my mind is a 33% probability.
aqc888: It would seem only news of a blue chip company or government placing an order for some detectors will get this share price moving. When Kromek does get an order from such an institution the market will finally wake up to the potential on offer here. You can be sure that Simon Thompson will be be there to tip Kromek yet again to give the share price an added boost.
b00mb0y: Aqc…… “I’m satisfied with my holding as Kromek are valued at 24p by equity development without the detector.” That means jack sh1t. The share price and the market tells us otherwise. “Seems like there may well be no news on the biological pathogen detector till the end of the year” and yet we were told “in the coming days” by Arnab in March. (Promises,promises) “ Even if the biological pathogen detector doesn’t work you’re only going to make modest losses, if any. It sounds to me like you are also losing faith, Aqc. Fruitloops “ Barring a major upset like a shareholder rebellion, AGMs are rarely of much consequence.” then why was everyone waiting for today and blogging about it with eagerness? Deedledee “ Can anyone summarise the AGM outcome? Share price has dipped. Why?” Because faith has all but totally gone! This share is now a massive gamble. If (a big IF) it comes good then great but a massive gamble! I’m gambling on the Big IF!
aqc888: I’ll pay more attention to your next Kromek prediction Dave! I’m resigned to the fact that the Kromek board of directors have such little trust from investors now (see skid on lse board) that only hard evidence of the detector working from a third party lab, plus evidence of orders from clients will shift this share price up. I’m expecting that to happen on the 14th September at the defence trade show. Until then I predict the share price will keep fluctuating between 18-21p
aqc888: Hopefully the ‘positive results’ the CEO and Simon Thompson talk of will be released later this month. When they are released we should see the strongest spike in the share price yet. share price should get to Simon Thompson’s target of ‘28p and well beyond’ at that point.
aqc888: I agree Mick. The old system DARPA are using is completely outdated compared with what Kromek could have achieved here. Huge potential in so many settings for this detector. Kromek with their 2year head start on the competition (started work in 2018). With their various patented intellectual property the CEO and ST speak of. Plus Kromek having secured £10m worth of government research funding for the biological pathogen detector (funds that won’t be available to competitors). All of this give Kromek a huge first mover advantage. Their competitive advantage or “economic moat” as Warren Buffet would put it should be substantial. Glad I increased Kromek to 10% of my portfolio a few weeks ago. Hopefully plenty more rises to come. Worst case scenario - the biological pathogen detector results are a failure. In this case Kromek have already secured 75% of this years sales in the radiation, hospital scanner and security screening business. Any future sales of the biological pathogen detector aren’t priced into the share price and government funding paid for all of the R&D. So perhaps the share price falls on the disappointment. Best case scenario- Kromeks main products continue to perform well and the biological pathogen detector sales eclipse the rest of the business with the huge global demand successful trial results will certainly bring. In this case scenario a £1 valuation for Kromek would be an extraordinarily undemanding valuation, given 1years profit from the biological pathogen detector could equal Kromeks entire market cap. Very exciting weeks ahead. I can anticipate a lot of turbulence in the share price in the coming weeks before the pathogen detector results are due (coming months according to ST). Some shareholders will see the sharp rise in the share price and won’t be able to resist banking the profits. Doing this before the positive results are released by the independent NHS lab will be a big mistake.
dougmachin: QuePassa - I think you're chasing a red herring here. Ventilators were a potential that never came about. That's all. If you wanna beat KMK with a stick, I would say there's other ways to do it. Ventilators aren't a part of KMK's core business. Agreed, they probably never should have mentioned anything in an RNS unless it was actually 100% going to result in sales, as this leads to 'boy who cried wolf' affect. From the presentation, I've moved so far on from that RNS. It's history. Not KMK's finest moment. But a small blip that in no way has affected KMK's core business. The presentation showed a quality company with some really exciting possibilities. Let's see where the share price is, this time next year. I am watching and would now add more.
aqc888: Who cares if the share price is a little up or down. When the results to the trial are out whatever ups or downs will be wiped out. If the results are positive, as the CEO says, I expect the share price to reach at least 30p by the end of the month. (With a little help from ST.) If the results are negative - Kromek just keep on ticking over - the medical, nuclear and security products will carry on selling. Share price will probably fall to 10-12p for a short while on the disappointment. I have a feeling I’ll kick myself for not buying more.
Kromek share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211025 18:05:09